Hormonal Management for Transfeminine Individuals

Jessica Abramowitz, Vin Tangpricha

Research output: Contribution to journalReview article

Abstract

Transfeminine individuals are treated with estradiol and anti-androgen agents to transition to a more feminine appearance. The physical changes that occur with estradiol therapy include breast development, body fat redistribution, and decreased muscle mass. Transfeminine treatment regimens require monitoring and dose adjustments to achieve appropriate physiologic targets to enhance feminization and decrease risk of adverse outcomes. Adverse effects associated with estradiol use include thromboembolic disease, macroprolactinoma, breast cancer, coronary artery disease, cerebrovascular disease, cholelithiasis, and hypertriglyceridemia. Benefits of hormonal treatment may include both an improvement in quality of life and a decrease in gender dysphoria.

Original languageEnglish (US)
Pages (from-to)313-317
Number of pages5
JournalClinics in Plastic Surgery
Volume45
Issue number3
DOIs
StatePublished - Jul 1 2018

Fingerprint

Estradiol
Feminization
Social Adjustment
Cerebrovascular Disorders
Prolactinoma
Cholelithiasis
Hypertriglyceridemia
Androgens
Adipose Tissue
Coronary Artery Disease
Breast
Quality of Life
Breast Neoplasms
Muscles
Therapeutics
Gender Dysphoria

Keywords

  • Estrogen treatment
  • Gender dysphoria
  • Hormonal therapy
  • Transfeminine
  • Transgender female

ASJC Scopus subject areas

  • Surgery

Cite this

Hormonal Management for Transfeminine Individuals. / Abramowitz, Jessica; Tangpricha, Vin.

In: Clinics in Plastic Surgery, Vol. 45, No. 3, 01.07.2018, p. 313-317.

Research output: Contribution to journalReview article

Abramowitz, Jessica ; Tangpricha, Vin. / Hormonal Management for Transfeminine Individuals. In: Clinics in Plastic Surgery. 2018 ; Vol. 45, No. 3. pp. 313-317.
@article{0b692b731a5b443d9d32155fb66ec06a,
title = "Hormonal Management for Transfeminine Individuals",
abstract = "Transfeminine individuals are treated with estradiol and anti-androgen agents to transition to a more feminine appearance. The physical changes that occur with estradiol therapy include breast development, body fat redistribution, and decreased muscle mass. Transfeminine treatment regimens require monitoring and dose adjustments to achieve appropriate physiologic targets to enhance feminization and decrease risk of adverse outcomes. Adverse effects associated with estradiol use include thromboembolic disease, macroprolactinoma, breast cancer, coronary artery disease, cerebrovascular disease, cholelithiasis, and hypertriglyceridemia. Benefits of hormonal treatment may include both an improvement in quality of life and a decrease in gender dysphoria.",
keywords = "Estrogen treatment, Gender dysphoria, Hormonal therapy, Transfeminine, Transgender female",
author = "Jessica Abramowitz and Vin Tangpricha",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.cps.2018.03.003",
language = "English (US)",
volume = "45",
pages = "313--317",
journal = "Clinics in Plastic Surgery",
issn = "0094-1298",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Hormonal Management for Transfeminine Individuals

AU - Abramowitz, Jessica

AU - Tangpricha, Vin

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Transfeminine individuals are treated with estradiol and anti-androgen agents to transition to a more feminine appearance. The physical changes that occur with estradiol therapy include breast development, body fat redistribution, and decreased muscle mass. Transfeminine treatment regimens require monitoring and dose adjustments to achieve appropriate physiologic targets to enhance feminization and decrease risk of adverse outcomes. Adverse effects associated with estradiol use include thromboembolic disease, macroprolactinoma, breast cancer, coronary artery disease, cerebrovascular disease, cholelithiasis, and hypertriglyceridemia. Benefits of hormonal treatment may include both an improvement in quality of life and a decrease in gender dysphoria.

AB - Transfeminine individuals are treated with estradiol and anti-androgen agents to transition to a more feminine appearance. The physical changes that occur with estradiol therapy include breast development, body fat redistribution, and decreased muscle mass. Transfeminine treatment regimens require monitoring and dose adjustments to achieve appropriate physiologic targets to enhance feminization and decrease risk of adverse outcomes. Adverse effects associated with estradiol use include thromboembolic disease, macroprolactinoma, breast cancer, coronary artery disease, cerebrovascular disease, cholelithiasis, and hypertriglyceridemia. Benefits of hormonal treatment may include both an improvement in quality of life and a decrease in gender dysphoria.

KW - Estrogen treatment

KW - Gender dysphoria

KW - Hormonal therapy

KW - Transfeminine

KW - Transgender female

UR - http://www.scopus.com/inward/record.url?scp=85048439400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048439400&partnerID=8YFLogxK

U2 - 10.1016/j.cps.2018.03.003

DO - 10.1016/j.cps.2018.03.003

M3 - Review article

C2 - 29908618

AN - SCOPUS:85048439400

VL - 45

SP - 313

EP - 317

JO - Clinics in Plastic Surgery

JF - Clinics in Plastic Surgery

SN - 0094-1298

IS - 3

ER -